Management

The Company is directed by Richard S. Kornbluth, MD, PhD, Chief Executive Officer and Chief Scientific Officer. Dr. Kornbluth invented Receptome's technology when he was an Associate Professor of Medicine at the University of California San Diego. He is also the founder of another UCSD spinout, Multimeric Biotherapeutics, Inc., a separately incorporated San Diego company that develops highly active forms of the TNF SuperFamily ligands.

Dr. Kornbluth graduated from Harvard with a undergraduate degree in Philosophy. He received his MD degree from New York Medical College and a PhD in Pathology from Columbia University. His clinical training includes Medical Residency at The Mount Sinai Hospital in New York City and a Pulmonary Medicine fellowship at the NewYork-Presbyterian/Columbia University Medical Center. His research training included studies in tumor biology with M. Judah Folkman at Harvard, in pulmonary research with Ines Mandl and Gerard M. Turino at Columbia, and cancer immunology with Thomas S. Edgington at The Scripps Research Institute in La Jolla, CA. At UCSD, Dr. Kornbluth worked in the Division of Infectious Diseases where he was a frequent collaborator with Douglas D. Richman, a renowned virologist and HIV researcher.

At UCSD, Dr. Kornbluth was an Attending Physician at the VA Medical Center and physician at the Owen Clinic (HIV care). He gained experience in clinical trials as Chair of the UCSD IRB for 10 years and Chair of the DSMB of the UCSD Cancer Center for 3 years. He is the author of over 60 peer-reviewed publications on virology, vaccines, and cancer immunotherapy and has received numerous NIH and private foundation grants. He has co-organized two international conferences on HIV immunology and is a member of the Scientific Advisory Committee of amFAR, The Foundation for AIDS Research.

At Receptome, LLC, Dr. Kornbluth directs company strategy and the development of its patented technology.